Proteomics

Dataset Information

0

Redefined complement C3c structures have significant increase in the plasma of ovarian cancer patients


ABSTRACT: Ovarian cancer (OC) ranks as the third most common gynecological cancer. Like other cancers, there still a need for effective biomarkers. To explore if plasma proteolytic products could serve as biomarkers, we devised a platform incorporating CyDye labeling, macroporous reversed-phase liquid chromatography, reducing/non-reducing SDS-PAGE, and fluorescence imaging. With paired preoperative and postoperative plasma samples, our analyses revealed a circulating complement C3 derivative present only at the disease state. This 145-kDa species under non-reducing condition split into 72-, 39-, and 29-kDa fragments upon reduction, reminiscent of the C3c structure. Mass spectrometric analyses showed multiple C-terminal ends in the C3c α’1 fragment, which were used differently among OC patients. The variety of ends were also observed in serum samples prepared using various complement activators, redefining C3c as a mix of multiple molecular entities. A commercialized ELISA assay targeting only the canonical C3c showed a strong correlation between increased plasma levels and the OC occurrence and pro-gression. Our results suggest that plasma proteolysis in complement deactivation is involved in ovarian tumorigenesis, and the resulting protein changes may help develop next-generation cancer biomarker.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma, Blood Serum

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Dong-Hao Chen  

LAB HEAD: Yeou-Guang Tsay

PROVIDER: PXD057890 | Pride | 2025-05-26

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
C3Ca1_LysC.ms2 Other
C3Ca1_LysC.raw Raw
C3Ca1_LysC_tide-search.target.txt Txt
C3Ca1_Trypsin.ms2 Other
C3Ca1_Trypsin.raw Raw
Items per page:
1 - 5 of 35
altmetric image

Publications

Redefined complement C3c structures have significant increase in the plasma of ovarian cancer patients.

Chen Dong-Hao DH   Chang Yi-Wen YW   Chien Chin-Hsiang CH   Torng Pao-Ling PL   Tsay Yeou-Guang YG  

Journal of the Chinese Medical Association : JCMA 20250516


<h4>Background</h4>Ovarian cancer (OC) is the third among the most common gynecological cancers. Effective biomarkers are required for OC as in the case of other cancers. Therefore, here we explored whether plasma proteolytic products could serve as potential biomarkers.<h4>Methods</h4>We devised a platform that incorporates CyDye labeling, macroporous reversed-phase liquid chromatography, reducing/non-reducing SDS-PAGE, and fluorescence imaging. Paired preoperative and postoperative plasma samp  ...[more]

Similar Datasets

2023-04-21 | PXD037987 | Pride
2010-07-31 | E-GEOD-23095 | biostudies-arrayexpress
2020-01-09 | PXD015504 | Pride
2023-03-11 | PXD038516 | Pride
2011-07-31 | E-GEOD-29979 | biostudies-arrayexpress
2010-05-18 | E-GEOD-16490 | biostudies-arrayexpress
2010-05-14 | E-GEOD-17944 | biostudies-arrayexpress
2022-10-12 | PXD036647 | Pride
2025-05-30 | PXD058514 | Pride
2025-05-30 | PXD058523 | Pride